SynthesisCancer2026
Outcomes of loncastuximab tesirine in heavily pretreated patients with diffuse large B-cell lymphoma, including the post-CAR T-cell therapy setting: A meta-analysis.
Synthesis in Cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
backgroundLoncastuximab tesirine, a CD19-directed antibody-drug conjugate, is a therapy for relapsed/refractory diffuse large B-cell lymphoma (DLBCL), including after chimeric antigen receptor T-cell therapy. This study summarized efficacy and safety across published cohorts.
methodsThe authors did a systematic review and meta-analysis of loncastuximab tesirine monotherapy in adults with relapsed or refractory DLBCL. They searched PubMed, Embase, and the Cochrane Library from inception to October 25, 2025, plus American Society of Hematology 2025 abstracts. They pooled single-arm proportions using random-effects proportional meta-analyses with Freeman-Tukey transformation and reconstructed individual patient data from Kaplan-Meier curves for time-to-event pooling (protocol: PROSPERO CRD420251156779). Seven studies (596 patients) met inclusion criteria.
resultsSeven studies (596 patients) contributed to clinical outcomes across all analyses. Pooled overall response was 45.76% (95% CI, 28.75-63.28; I
conclusionsLoncastuximab tesirine shows clinically meaningful activity in heavily pretreated R/R DLBCL, including post-CAR T-cell therapy settings, with frequent but manageable cytopenias. Pooled estimates showed substantial heterogeneity, driven mainly by real-world cohorts, and should be interpreted with caution.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.